Q2 2026 Edwards Lifesciences Corp Earnings Call Transcript
Key Points
- Edwards Lifesciences Corp (EW) reported a stronger than expected second quarter sales growth of 12.5%, driven by multiple therapies across TAVR, mitral, tricuspid, and surgical segments.
- The company increased its full-year 2026 sales growth guidance for TAVR, TMTT, and total company, reflecting confidence in sustained performance.
- Edwards Lifesciences Corp (EW) continues to demonstrate leadership in advancing high-quality science and innovation, with significant clinical presentations at the New York Valves Conference.
- The company maintains a strong and flexible balance sheet with approximately $2.9 billion in cash and cash equivalents, supporting growth and long-term value creation.
- Edwards Lifesciences Corp (EW) is on track to achieve its long-term target of 10% total company sales growth on average, supported by a comprehensive portfolio and strategic platforms.
- The company faces risks and uncertainties that could cause actual results to differ materially from forward-looking statements, as highlighted in their SEC filings.
- Foreign exchange headwinds impacted the adjusted gross profit margin, which is expected to be at the lower end of the full-year guidance.
- The effective tax rate is expected to be at the high end of the original range due to Pillar Two impact and changes to California law restricting the usage of R&D credits.
- The second half of 2026 is expected to have artificially lower growth rates due to high comps from the previous year, particularly in the third quarter.
- There is potential variability in growth rates within therapeutic areas as the company creates and shapes new therapeutic categories and achieves clinical, regulatory, and commercial milestones.
Greetings, and welcome to the Edwards Life Sciences second-quarter 2026 earnings conference call. (Operator Instructions) As a reminder, this conference call is being recorded.
It is now my pleasure to introduce Gerianne Sarte, Head of Investor Relations. Thank you. You may begin.
Good afternoon, and thank you for joining us. With me on todayâs call is our CEO, Bernard Zovighian; and our CFO, Doretta Mistras. Also joining us for the Q&A portion of the call will be Dan Lippis, our global leader of TAVR, and Daveen Chopra, who has global responsibility for TMTT, surgical, and IHFM.
After the close of regular trading, Edwards Lifesciences released second quarter 2026 financial results. During todayâs call, management will discuss the results included in the press release and accompanying financial schedules, and then use the remaining time for Q&A.
Please note that management will be making forward-looking statements that are based on estimates, assumptions, and
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
